Loading…
ADC Therapeutics SA is projected to rise to $1.78 by 2027, a +38% move from its current price of $1.29. ADCT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $1.23 | $1.29 | $1.35 | -0.02% |
| Jul 15 | $1.20 | $1.29 | $1.38 | -0.05% |
| Jul 16 | $1.19 | $1.29 | $1.40 | -0.07% |
| Jul 17 | $1.17 | $1.29 | $1.42 | -0.10% |
| Jul 18 | $1.16 | $1.29 | $1.43 | -0.12% |
| Jul 19 | $1.15 | $1.29 | $1.45 | -0.15% |
| Jul 20 | $1.13 | $1.29 | $1.46 | -0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.13 | $1.29 | $1.46 | -0.17% |
| Week 2 | $1.07 | $1.29 | $1.54 | -0.34% |
| Week 3 | $1.03 | $1.28 | $1.60 | -0.51% |
| Week 4 | $0.9945 | $1.28 | $1.65 | -0.68% |
| Week 5 | $0.9636 | $1.28 | $1.70 | -0.85% |
| Week 6 | $0.9363 | $1.28 | $1.74 | -1.02% |
| Week 7 | $0.9117 | $1.27 | $1.78 | -1.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ADC Therapeutics SA is a healthcare company that provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, which has received accelerated approval from the U.S. Food and Drug Administration and conditional approvals from the European Commission and the China National Medical Products Administration for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland. It is pursuing expansion of ZYNLONTA into international markets and earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma and marginal zone lymphoma, as a single agent and in combination through LOTIS-5 and LOTIS-7 trials and investigator-initiated trials. It is also developing a CD-22 targeted compound and ADCT-602 in a Phase 1/2 IIT, with a pre-clinical pipeline targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2.
ADC Therapeutics SA trades at $1.35 per share with a market capitalization of $171.71M and holds a rank of 3933. The stock sits in a small-cap space by rank and market cap, reflecting a limited, high-variance growth profile.
The 30-day price action sits in a near-term range, with a current technical picture that shows a neutral stance. The stock’s price outlook, according to the provided forecast, suggests a path of gradual upside across multiple years, culminating in substantially higher levels by 2050. The forecast implies a range of potential outcomes from a 2026 base around the current level to a peak in 2050, with a max price target in the forecast of $13.30.
The implied path includes year-by-year progressions, with the average price moving from $1.35 in 2026 toward higher levels later in the decade and beyond, and a max price indicating meaningful upside relative to today.
A major floor 24.2% below — a decisive break under it would weaken the trend.
The nearest floor, 24.2% below — buyers have tended to step in here.
The nearest ceiling, 167.4% above — a clean break opens room to run.
A major ceiling 278.3% above — clearing it would confirm fresh momentum.
Key ADCT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ADCT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.29 | Sell | $1.27 | Buy |
| MA 10 | $1.19 | Buy | $1.24 | Buy |
| MA 20 | $1.13 | Buy | $1.36 | Sell |
| MA 50 | $2.30 | Sell | $2.06 | Sell |
| MA 100 | $3.18 | Sell | $2.71 | Sell |
| MA 200 | $3.56 | Sell | $3.08 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.98 | Neutral |
| Stoch RSI (14) | 92.28 | Sell |
| CCI (20) | 117.61 | Buy |
| Williams %R (14) | -18.18 | Info |
| MACD (12,26,9) | 0.12 | Buy |
| ROC (12) | 12.17 | Buy |
| Bollinger %B (20,2) | 0.88 | Neutral |
| Stochastic %K (14) | 81.82 | Sell |
| TRIX (15) | -3.01 | Sell |
| Awesome (5,34) | -0.42 | Sell |
| Ultimate (7,14,28) | 66.72 | Neutral |
| Momentum (10) | 0.25 | Buy |
| Aroon Osc (25) | -12.00 | Sell |
| Hull MA (9) | 1.35 | Sell |
| ADX (14) | 42.57 | Sell |
| ATR (14) | 0.08 | Info |
Technical snapshot over the last 30 days shows NEUTRAL sentiment with RSI(14) at 40. The 50-day simple moving average stands at $2.45 and the 200-day simple moving average at $3.59. The price has a defined support at $0.978 and a resistance at $3.51.
The 30-day price range runs from $0.9625 to $1.89, illustrating limited near-term upside and notable resistance above current levels.
Overall near-term dynamics point to a balanced setup, with investors watching for tests of the $0.978 support or a break toward the $3.51 resistance if momentum shifts.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.978 | $1.29 | $1.91 | 0% | Neutral | |
| $1.32 | $1.78 | $2.59 | +38% | Bullish | |
| $1.32 | $1.88 | $2.90 | +46% | Bullish | |
| $1.09 | $1.62 | $2.61 | +25% | Bullish | |
| $1.15 | $1.78 | $2.98 | +38% | Bullish | |
| $1.12 | $1.81 | $3.12 | +40% | Bullish | |
| $1.00 | $1.68 | $2.98 | +30% | Bullish | |
| $1.41 | $2.44 | $4.46 | +89% | Bullish | |
| $1.52 | $2.72 | $5.10 | +111% | Bullish | |
| $1.41 | $2.60 | $4.97 | +102% | Bullish | |
| $1.65 | $3.55 | $7.42 | +175% | Bullish | |
| $2.47 | $5.49 | $12.62 | +325% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.978 | $1.29 | $1.55 | +0.00% |
| August 2026 | $1.01 | $1.21 | $1.52 | -5.99% |
| September 2026 | $1.03 | $1.26 | $1.61 | +4.03% |
| October 2026 | $1.12 | $1.38 | $1.79 | +9.38% |
| November 2026 | $1.13 | $1.41 | $1.85 | +2.06% |
| December 2026 | $1.15 | $1.44 | $1.91 | +2.19% |
Click any year to see its month-by-month ADCT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ADCT could reach as high as $1.91, with a base case around $1.29 and support toward $0.978 — roughly 0% from $1.29. A consolidation phase looks the most probable path here.
Expect ADCT to range from $1.32 to $2.59 through 2027. The $1.78 average target implies a +38% move from current prices. That is up +38% on the projected 2026 average. Momentum favours further upside here.
The ADCT price prediction for 2028 points to an average of $1.88 (low $1.32, high $2.90) — a potential gain of +46% on today's $1.29. Buyers look set to stay in control over this stretch.
In 2029, ADCT is projected to trade between $1.09 and $2.61, averaging $1.62 — a potential gain of +25% from today's $1.29. That is -14% versus the projected 2028 average. Momentum favours further upside here.
ADC Therapeutics SA's 2030 outlook centres on $1.78, within a $1.15 to $2.98 range. That is up +10% on the projected 2029 average. That marks a +38% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, ADCT could reach as high as $3.12, with a base case around $1.81 and support toward $1.12 — roughly +40% from $1.29. Momentum favours further upside here.
Expect ADCT to range from $1.00 to $2.98 through 2032. The $1.68 average target implies a +30% move from current prices. That is -7% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
The ADCT price prediction for 2033 points to an average of $2.44 (low $1.41, high $4.46) — a potential gain of +89% on today's $1.29. Momentum favours further upside here.
In 2034, ADCT is projected to trade between $1.52 and $5.10, averaging $2.72 — a potential gain of +111% from today's $1.29. That is up +12% on the projected 2033 average. Buyers look set to stay in control over this stretch.
ADC Therapeutics SA's 2035 outlook centres on $2.60, within a $1.41 to $4.97 range. That is -5% versus the projected 2034 average. That marks a +102% change versus current levels. Momentum favours further upside here.
By 2040, ADCT could reach as high as $7.42, with a base case around $3.55 and support toward $1.65 — roughly +175% from $1.29. Buyers look set to stay in control over this stretch.
Expect ADCT to range from $2.47 to $12.62 through 2050. The $5.49 average target implies a +325% move from current prices. That is up +54% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ADCT today (≈ 775.193798 ADCT) could be worth
$4,252.86
+$3,252.86 (+325%) by 2050 · US Dollar
Based on the average projected ADCT price of $5.49 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ADCTwould be worth at today's price.
$1,000 invested in ADCT on Jul 10, 2025 (≈ 303.030307 ADCT) would be worth
$390.91
-$609.09 (-60.9%) today · 0.39× · US Dollar
Based on a ADCT entry price of $3.3 vs. today's $1.29.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.19 | $1,084.03 | +8.4% |
| 1 month ago | $1.1 | $1,172.73 | +17.3% |
| 3 months ago | $3.74 | $344.92 | -65.5% |
| 6 months ago | $3.82 | $337.7 | -66.2% |
| 1 year ago | $3.3 | $390.91 | -60.9% |
| All time (5.0y) ago | $22.92 | $56.28 | -94.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ADCT forecast.
Our base-case forecast reaches $2.60 around 2034.
Implied market cap at $2.60: $330.7M
The multi-year forecast shows a bullish trajectory, with the 2030 average price at $1.88 and a 39.1% ROI, supported by a bullish sentiment. The 2040 forecast shows an average of $3.72 with a 175.9% ROI, remaining in a bullish territory.
By 2050, the forecast projects an average price of $5.78 with a 328.4% ROI and a bullish sentiment, indicating substantial upside potential over the long horizon. Across the years, the model provides a wide price corridor, including a 2033 average of $2.60 and a 2034 average of $2.89, with occasional higher ROIs (e.g., 92.7% in 2033 and 114% in 2034). The forecast also notes a very high long-run volatility context, reflecting the 100% annualized volatility figure observed.
Overall, these are estimates, not guarantees, and investors should consider the potential for both meaningful gains and significant volatility.
Tap a question to reveal the answer.
2030: min $1.18, avg $1.88, max $3.22; ROI 39.1%; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising averages (e.g., avg $1.90 in 2027, $5.78 by 2050) and a long-run max of $13.30, with ROI up to 328.4% by 2050, though these are estimates and involve volatility.
Yes. The 2035 forecast lists min $1.42, avg $2.74, max $5.39 with ROI 103.2% and a bullish sentiment.
$1.35 per share.
The 30-day range is $0.9625 to $1.89. RSI(14) is 40, SMA50 is $2.45, SMA200 is $3.59, and support is $0.978 with resistance at $3.51. Sentiment is NEUTRAL.
ADC Therapeutics SA Community Discussion
0Share your ADC Therapeutics SA price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.